While established tumor growth in neuroblastoma xenografts was not inhibited, systemic administration of AZD9150 led to reversal of STAT3-mediated resistance to cisplatin, as indicated by a twofold decrease in the IC50 for cisplatin [64]. This evidence concerns the gene STAT3 and neoplasm.